厦门市亨瑞生化有限公司

XIAMEN HENRYBIOCHEM CO.,LTD

Contact Us

 API and Intermediates 
 Tel: 86 592 6055157 
 Fax: 86 592 6055177 
 Email: sales@henrybiochem.com 
 Custom synthesis and Technical service 
 Tel: 86 592 6055199 
 Fax: 86 592 6055177 
 Email: pyhou@henrybiochem.com

New Keletra (Lopinavir/Ritonavir)
    
    On April 27, 2010, FDA approved a new dosing regimen for Kaletra (lopinavir/ritonavir) tablets and oral solution. Kaletra can be administered once daily (800/200 mg) in patients with less than three lopinavir resistance associated substitutions. Once daily administration of KALETRA is not recommended for adult patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. Of note, once daily administration of Kaletra is not recommended in pediatric patients.



Original source:http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm209940.htm